| Literature DB >> 33578793 |
Maria Panagopoulou1, Manel Esteller2,3,4,5, Ekaterini Chatzaki1,6.
Abstract
Breast cancer (BC) is a leading cause of death between women. Mortality is significantly raised due to drug resistance and metastasis, while personalized treatment options are obstructed by the limitations of conventional biopsy follow-up. Lately, research is focusing on circulating biomarkers as minimally invasive choices for diagnosis, prognosis and treatment monitoring. Circulating cell-free DNA (ccfDNA) is a promising liquid biopsy biomaterial of great potential as it is thought to mirror the tumor's lifespan; however, its clinical exploitation is burdened mainly by gaps in knowledge of its biology and specific characteristics. The current review aims to gather latest findings about the nature of ccfDNA and its multiple molecular and biological characteristics in breast cancer, covering basic and translational research and giving insights about its validity in a clinical setting.Entities:
Keywords: biomarker; breast cancer; circulating cell-free DNA; liquid biopsy; monitoring; prognosis
Year: 2021 PMID: 33578793 PMCID: PMC7916622 DOI: 10.3390/cancers13040728
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639